Draft:Liver cell damage

From Wikipedia, the free encyclopedia
(Redirected from User:CharlesMo10/sandbox)


Liver cell damage (also known as hepatocellular injury) refers to biological or physical damage to the liver cells or hepatocytes as a result of different pathological changes. Liver cell damage involves apoptosis or necrosis of liver cells or hepatocytes. Common signs and symptoms can be fever, jaundice, right upper quadrant abdominal pain, fatique and nausea. Causes of liver cell damage involve oxidative stress from free radicals and antioxidant consumption, immune responses against foreign substances and virus infections or nonspecific causes which can be environmental or genetic factors. Diagnosis of liver cell damage encompasses detections of biomarkers which are enzymes in the liver that reflect inflammation or hepatocyte damage condition. Therapeutic interventions of liver cell damage can be specific for liver cell damage originated from different causes. Examples of therapeutic interventions are liver transplantation, stem cell therapy, antioxidants, vaccinations and immunosuppressants.

Types of liver cell damage[edit]

Liver cell damage can be in the form of necrosis, apoptosis or both. Necrosis can be resulting from deteriorated apoptosis, particularly mitochondrial dysfunctioning process in apoptosis, which directs to ATP depletion and oxidative stress.

Apoptosis[edit]

Apoptosis (programmed cell death), characterized by chromatin condensation, cytoplasm shrinkage and DNA fragmentation, is more predominantly observed in all types of liver cell injuries. It can be stimulated under pathological conditions such as hepatotoxicity, radiation exposure and infections with hepatotropic viruses.

Apoptosis occurs in two pathways, namely extrinsic and intrinsic pathways.[1]

In extrinsic pathways, death receptors bind with ligands(e.g. TNF-α, Fas, and tumor necrosis factor–related apoptosis-inducing ligand),forming the death-inducing signaling complex. This is by activation of caspase 8 which is the initiator caspases that activate executioner caspases that are responsible for the protein cleavage in apoptosis.

In intrinsic pathways, in the presence of apoptotic inducing signal, BH3 family protein(Bid/Bim) activates Bax/Bak which are pro-apoptotic proteins that insert into the mitochondria membrane, causing membrane outer membrane permeabilization(MOMP) and release of cytochrome c from mitochondria which further activating caspases that cleaves proteins in apoptosis. MOMP increases membrane permeability, thereby promoting leakage of mitochondrial material into the cytosol.

Necrosis[edit]

Necrosis is an irreversible cellular process, often driven by the increase in oxidative stress level in cells, particularly hepatocytes. Properties of necrotic cells involve oncosis which is cell swelling due to inability of maintaining cell ion potentials, karyolysis due to enzymatic degradation of chromatin and breaking of cell membrane.[2]

Signs and symptoms[edit]

Signs and symptoms can be different according to various types of liver cell damage manifestations in disease conditions.

For non-alcoholic fatty liver disease(NAFLD),

signs

  • enlarged liver

symptoms

  • fatigue
  • abdominal discomfort

For Autoimmune hepatitis(AIH),

signs

  • fever
  • jaundice
  • right upper quadrant abdominal pain

symptoms

  • fatique
  • Nausea

For hepatitis b infections,

signs

  • fever
  • jaundice
  • dark urine

symptoms

  • loss of appetite
  • Nausea

For alcoholic liver disease,

signs

  • metabolic acidosis

symptoms

  • coma
  • sweating
  • nausea

Causes[edit]

Oxidative stress[edit]

Oxidative stress indicates disequilibrium in the levels of oxidants and antioxidants where there is excess level of oxidants due to overproduction of ROS or reduced removal of ROS and low levels of antioxidants due to high consumptions of antioxidants. Free radicals are molecules containing unpaired electrons that are derived from chemicals and can be either nitrogen or oxygen based. Examples of free radicals contain superoxide, peroxyl, oxygen based molecules are also named reactive oxygen species(ROS). Some free radical metabolites are generated from chemicals or drugs that induce hepatotoxicity which results in liver cell damage(necrosis and apoptosis). Liver acts as the main site of drug metabolism. The metabolites are formed from the metabolism system in liver, involving drug oxidation phase by p450 enzymes. Cytochrome P4502E1 or CYP540 in particular participates in biotransformations of substances including ethanol, CCl4, Acetaminophen(APAP) and N-nitrosodimethylamine(NDMA) which all contribute to oxidative stress formation.[3]

Oxidative stress activates MAPKs and JNKs which in turn accumulates the oxidative stress. Ultimately, lipid peroxidation increases followed by activation of membrane permeability transition and migration of mitochondrial proteins(e.g.apoptosis inducing factor AIF, endonuclease G) trigger the DNA fragmentation, liver cell apoptosis and necrosis.[4]

alcohol metabolism

In alcohol metabolism, oxidative stress originates from ethanol conversion to acetaldehyde by either aldehyde dehydrogenase, which converts acetaldehyde into acetyl radical and hydrogen or CYP2E1-catalyzed oxidation, which deprives the reducing agent NADH(nicotinamide adenine dinucleotide).[5] ALD(alcoholic liver disease) is the liver disease caused by alcohol consumption. Oxidative stress as a result of alcohol consumption leads to increase in expressions of proinflammatory cytokines such as TNF-ɑ that facilitates death receptors to enhance apoptosis of liver cells. Some studies suggest alcohol consumption increases iron concentration in hepatocytes which amplifies oxidative stress and lipid peroxidation while others do not. Animals with ALD manifests impaired function in liver regeneration.[6]

Paracetamol induced liver injury

In Paracetamol metabolism, with the depletion of GSH reserve in the body, NAPQI forms protein-NAPQI adduct with hepatic cytosolic proteins, especially mitochondrial proteins. Since GSH serves as the antioxidant agents, depletion of GSH causes oxidative stress. NAPQI can also be the source of oxidative stress. Binding of NAPQI to mitochondrial antioxidant proteins such as glutathione peroxidase renders the protein inactive and excessive oxidative stress is introduced in the mitochondria. Binding of NAPQI to CaATPase(Calcium dependent ATPase) inactivates CaATPase, resulting in accumulation of calcium in cells, activation of calcium dependent degradative enzymes and liver cell necrosis.[7]

Immune system responses[edit]

Cell damage may arise from immune system activation in liver against foreign substances.

In alcohol consumption, acetaldehyde binds with macromolecules such as proteins in hepatocytes. The acetaldehyde-protein adduct can be recognized by infiltrated neutrophils as antigens, triggering cellular immune response of phagocytosis. The acetaldehyde can also form highly adduct with malondialdehyde, a metabolite from lipid peroxidation, to elicit both cellular immune response or humoral immune responses and consequently leading to hepatic cell deaths.[8]

Viral infections[edit]

Hepatitis A,hepatitis B and hepatitis C are the most common types of inflammation seen in infected cases. Patients can be infected through different modes of transmission, including viral contact with food, water or contaminated objects, genetical transmission, sexual transmission and blood transmission.[9]

Hepatitis C protein produced from RNA genome of virus hepatitis C possess both antiapoptotic and apoptotic abilities. Upon binding to death domain of FADD(fas associated death domain), it promotes expressions of FADD. Both TNF-α and FAS induced apoptosis get upregulated.[10]

Hepatitis b virus morphology

Hepatitis B virus contains both apoptotic and anti-apoptotic properties. Lymphocytes infiltration such as macrophage kupffer cells in hepatocyte apoptotic sites presents activities of host lymphocytes against antigens. Innate immune responses occur after internalization of virus protein HBsAg by kupffer cells, synthesis of IL-6, TNF, and CXCL8 and NK(natural killer) cells activation. NK cells kill infected hepatocytes non-specifically which accounts for most of liver cell damage.

Anti-HBs antibodies work by binding with HBsAg, neutralizing it and thereby halting the further spread of virus infections to other hepatocytes through internalization of HBV via sodium taurocholate co-transporting polypeptide (NTCP) receptors. However, HBsAg transforms into spherical filamentous subviral particles (SVPs) which in turn neutralize anti-HBs antibodies. As a result, virus gets uncontrolled and spreads out to other hepatocytes. HBsAg also turns off adaptive immune response by downregulating IL-12 production through inhibiting of c-Jun using phosphorylation. C-Jun is a transcription factor for interleukin 12. This reduces production of a cytokine essential for activation of T cells and proliferations of T cells.[11]

Other non specific causes

Autoimmune Hepatitis (AIH) is chronic disease of progressive inflammation of the liver from unknown causes. Despite the unknown nature of the specific cause of the liver cell damage, it is most likely related to genetic factors, environmental causation, and failure of the immune system.[12]

Non-alcoholic fatty liver disease (NAFLD) is a disease which is caused by fat accumulation in the liver of who consume little to no alcohol. NAFLD includes of a spectrum of liver diseases ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which brings inflammation and liver cell damage. NAFLD results from a combination of genetic and environmental factors. NAFLD have symptoms such as fatigue, abdominal discomfort and an enlarged liver.

Diagnosis[edit]

Diagnosis of liver cell damages consists of a combination of medical history, physical examination, and laboratory tests. The medical history examines alcohol and drug use, and family history. The physical examination looks for signs of liver damage, such as jaundice and an enlarged liver.[13]Blood tests are used to assess liver function and detect liver damage, such as elevated levels of liver enzymes: alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transferase (GGT) and bilirubin, prothrombin time (PT), the international normalized ratio (INR), total protein and albumin. The different level of enzymes indicate the area of damage. [14] Disproportionate increase in ALT and AST levels to alkaline phosphatase and bilirubin level indicate hepatocellular disease. A disproportionate increase in alkaline phosphatase and bilirubin to ALT and AST level indicate a cholestatic liver disease. Albumin level indicate liver functioning activity rate. Elevation of cytokeratin 18 neoantigen (M30) is indicative for continuous hepatocyte apoptosis in HCV patients.[15]

Therapeutic intervention[edit]

Vaccination[edit]

Hepatitis B vaccine is in the form of hepatitis b surface antigen and is able to sensitize adaptive immune system of the recipients.[16]

Cell death pathway inhibitors[edit]

Cell death pathways consist of many molecules which can be targets of therapeutic interventions. Inhibition of cell apoptotic pathway cytokines or proteins prevent the stream cell death signaling. Pan-caspase inhibitor, IDN 6556 is a caspase inhibitor involved in inhibiting hepatocyte apoptosis. Anti-TNF α agents such as etanercept, which is a TNF receptor protein that binds with serum TNF α, neutralizing and inactivating it.[17] Infliximab is the monoclonal antibody that binds to TNF receptors and interfere with the interactions of TNF with its receptor and also cause cell lysis of kupffer cells that secrete TNF. [18] N-methyl-4-isoleucine cyclosporine (NIM811) hinders the membrane permeability transition and leads to reduction in liver cell injury. JNK(c-Jun N-terminal kinases) inhibitors may be applicable to paracetamol-induced liver injury and non-alcoholic liver disease.[19]

Antioxidant[edit]

Current therapeutic interventions of antioxidants focus on prevention of liver cell damage rather than treatment.

Antioxidants such as carnosic acid have shown positive impacts of hepatoprotection and antioxidant in mices with paracetamol induced liver injury.[20] N-acetylcysteine, the precursor molecule of the antioxidants GSH(glutathione) and vitamin C have demonstrated hepatoprotective effects in ALD mices by improving function of mitochondria and further exposure to excess oxidative stress. [21] However, many studies proved effectiveness in animals but not in humans and more exploratory and confirmatory studies remain to be conducted to examine underlying mechanisms of various antioxidants in prevention and treatment of liver diseases with liver cell damage.[22]

Immunosuppressant[edit]

For autoimmune liver diseases, immunosuppressive drugs are often used to suppress the immune system and prevent further damage to the liver. A widely used immunosuppressant is azathioprine.[23] Azathioprine inhibits DNA and RNA replication of immune cells, and therefore controls the number of immune cells that attack the liver. When Azathioprine enters the liver, it is converted into 6-mercaptopurine, which displays immunosuppressive effects.[24] Dosage of immunosuppressants can be effective with a mixture of steroids as well, such as prednisolone. However, long-term use of these medications may be associated with side effects such as weight gain, mood changes, increased risk of infection, and bone loss.[25]

Liver Transplantation[edit]

Liver transplantation is a surgical procedure that involves replacing a damaged or diseased liver with a healthy liver from a deceased or living donor. This treatment option is considered when liver cell damage is severe and irreversible, such as in cases of end-stage liver disease or acute liver failure. The damaged liver is removed and the new liver is implanted into the recipient's body. Liver transplantation offers an effective treatment for individuals with liver cell damage, as it can significantly improve their quality of life and increase their chances of survival. However, this procedure requires a lifelong dosage of immunosuppressive drugs to prevent organ rejection.[26]

Stem Cell Therapy[edit]

The application of stem cell therapy is a potential treatment intervention for liver cell damage. The use of mesenchymal stem cells (MSCs) is one method. MSCs are adult stem cells easily found in various tissues, including bone marrow, umbilical cord, fat, and others. MSCs can control the immune system and possess anti-inflammatory properties. MSCs have the ability to regulate the immune system and also regulate the innate and adaptive differentiation of cells, such as macrophages, helper T cells, and B cells. This results in a reduction of inflammation and improvement of tissue damage. [27] Additionally, induced pluripotent stem cells (iPSCs) derived from a patient's cells, such as skin cells, can potentially be used to generate liver cells that can be transplanted back into the patient. This personalized approach holds promise for AIH treatment, as it can potentially reduce the risk of rejection. However, stem cell therapy for AIH is still in the early stages of research and clinical trials. Extensive studies are needed to evaluate the safety, efficacy, and long-term outcomes of stem cell therapy in AIH patients.[28]

  1. ^ Malhi, H; Gores, GJ (May 2008). "Cellular and molecular mechanisms of liver injury". Gastroenterology. 134 (6): 1641–54. doi:10.1053/j.gastro.2008.03.002. PMC 2553363. PMID 18471544.
  2. ^ Malhi, H; Gores, GJ (May 2008). "Cellular and molecular mechanisms of liver injury". Gastroenterology. 134 (6): 1641–54. doi:10.1053/j.gastro.2008.03.002. PMC 2553363. PMID 18471544.
  3. ^ Li, S; Tan, HY; Wang, N; Zhang, ZJ; Lao, L; Wong, CW; Feng, Y (2 November 2015). "The Role of Oxidative Stress and Antioxidants in Liver Diseases". International Journal of Molecular Sciences. 16 (11): 26087–124. doi:10.3390/ijms161125942. PMC 4661801. PMID 26540040.
  4. ^ Jaeschke, H; McGill, MR; Ramachandran, A (February 2012). "Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity". Drug Metabolism Reviews. 44 (1): 88–106. doi:10.3109/03602532.2011.602688. PMC 5319847. PMID 22229890.
  5. ^ Tsukamoto, Hidekazu; Lu, Shelly C. (June 2001). "Current concepts in the pathogenesis of alcoholic liver injury". The FASEB Journal. 15 (8): 1335–1349. doi:10.1096/fj.00-0650rev. PMID 11387231.
  6. ^ Muriel, P. (2009). "Role of free radicals in liver diseases". Hepatology International. 3 (4): 526–536. doi:10.1007/s12072-009-9158-6. PMC 2790593. PMID 19941170.
  7. ^ Yoon, E; Babar, A; Choudhary, M; Kutner, M; Pyrsopoulos, N (28 June 2016). "Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update". Journal of Clinical and Translational Hepatology. 4 (2): 131–42. doi:10.14218/JCTH.2015.00052. PMC 4913076. PMID 27350943.
  8. ^ Tsukamoto, Hidekazu; Lu, Shelly C. (June 2001). "Current concepts in the pathogenesis of alcoholic liver injury". The FASEB Journal. 15 (8): 1335–1349. doi:10.1096/fj.00-0650rev. PMID 11387231.
  9. ^ Mehta, Parth; Reddivari, Anil Kumar Reddy (2024). "Hepatitis". StatPearls. StatPearls Publishing. PMID 32119436.
  10. ^ Malhi, H; Gores, GJ (May 2008). "Cellular and molecular mechanisms of liver injury". Gastroenterology. 134 (6): 1641–54. doi:10.1053/j.gastro.2008.03.002. PMC 2553363. PMID 18471544.
  11. ^ Zhao, F; Xie, X; Tan, X; Yu, H; Tian, M; Lv, H; Qin, C; Qi, J; Zhu, Q (2021). "The Functions of Hepatitis B Virus Encoding Proteins: Viral Persistence and Liver Pathogenesis". Frontiers in Immunology. 12: 691766. doi:10.3389/fimmu.2021.691766. PMC 8387624. PMID 34456908.
  12. ^ Linzay, Catherine D.; Sharma, Bashar; Pandit, Sudha (2024). "Autoimmune Hepatitis". StatPearls. StatPearls Publishing. PMID 29083819.
  13. ^ Smith, Andrew; Baumgartner, Katrina; Bositis, Christopher (15 December 2019). "Cirrhosis: Diagnosis and Management". American Family Physician. 100 (12): 759–770. PMID 31845776.
  14. ^ Lala, Vasimahmed; Zubair, Muhammad; Minter, David A. (2024). "Liver Function Tests". StatPearls. StatPearls Publishing. PMID 29494096.
  15. ^ Malhi, H; Gores, GJ (May 2008). "Cellular and molecular mechanisms of liver injury". Gastroenterology. 134 (6): 1641–54. doi:10.1053/j.gastro.2008.03.002. PMC 2553363. PMID 18471544.
  16. ^ "Hepatitis B Vaccine (Recombinant)". go.drugbank.com. Retrieved 27 March 2024.
  17. ^ "Etanercept". Retrieved 27 March 2024.
  18. ^ "Infliximab". Retrieved 27 March 2024.
  19. ^ Malhi, H; Gores, GJ (May 2008). "Cellular and molecular mechanisms of liver injury". Gastroenterology. 134 (6): 1641–54. doi:10.1053/j.gastro.2008.03.002. PMC 2553363. PMID 18471544.
  20. ^ Malhi, H; Gores, GJ (May 2008). "Cellular and molecular mechanisms of liver injury". Gastroenterology. 134 (6): 1641–54. doi:10.1053/j.gastro.2008.03.002. PMC 2553363. PMID 18471544.
  21. ^ Wang, Xiaoxu; Liu, Bin; Liu, Yanjun; Wang, Yuliu; Wang, Zhigao; Song, Yu; Xu, Jie; Xue, Changhu (September 2023). "Antioxidants ameliorate oxidative stress in alcoholic liver injury by modulating lipid metabolism and phospholipid homeostasis". Lipids. 58 (5): 229–240. doi:10.1002/lipd.12377. PMID 37547958.
  22. ^ Li, S; Tan, HY; Wang, N; Zhang, ZJ; Lao, L; Wong, CW; Feng, Y (2 November 2015). "The Role of Oxidative Stress and Antioxidants in Liver Diseases". International Journal of Molecular Sciences. 16 (11): 26087–124. doi:10.3390/ijms161125942. PMC 4661801. PMID 26540040.
  23. ^ Kim, Ja Kyung (25 February 2023). "Treatment of Autoimmune Hepatitis". The Korean Journal of Gastroenterology. 81 (2): 72–85. doi:10.4166/kjg.2023.011. PMID 36824035.
  24. ^ Terziroli Beretta-Piccoli, B; Mieli-Vergani, G; Vergani, D (7 September 2017). "Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments". World Journal of Gastroenterology. 23 (33): 6030–6048. doi:10.3748/wjg.v23.i33.6030. PMC 5597495. PMID 28970719.
  25. ^ Pape, Simon; Schramm, Christoph; Gevers, Tom JG (November 2019). "Clinical management of autoimmune hepatitis". United European Gastroenterology Journal. 7 (9): 1156–1163. doi:10.1177/2050640619872408. PMC 6826525. PMID 31700628.
  26. ^ Dababneh, Yara; Mousa, Omar Y. (2024). "Liver Transplantation". StatPearls. StatPearls Publishing. PMID 32644587.
  27. ^ Li, TT; Wang, ZR; Yao, WQ; Linghu, EQ; Wang, FS; Shi, L (21 September 2022). "Stem Cell Therapies for Chronic Liver Diseases: Progress and Challenges". Stem Cells Translational Medicine. 11 (9): 900–911. doi:10.1093/stcltm/szac053. PMC 9492280. PMID 35993521.
  28. ^ Lotfy, A; Elgamal, A; Burdzinska, A; Swelum, AA; Soliman, R; Hassan, AA; Shiha, G (7 July 2021). "Stem cell therapies for autoimmune hepatitis". Stem Cell Research & Therapy. 12 (1): 386. doi:10.1186/s13287-021-02464-w. PMC 8262021. PMID 34233726.